Innovations in Pharma Science - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Innovations in Pharma Science
Pharmaceutical Technology is pleased to recognize the winners of its Innovations in Pharma Science Awards.

Pharmaceutical Technology
Volume 32, Issue 12, pp. 46-47

Dual-variable domain immunoglobulin (DVD-Ig)

Created by Chengbin Wu and Tariq Ghayur

Biologics, Abbott Laboratories (Abbott Park, IL)


(COURTESY OF MERCK RESEARCH LABORATORIES)
Targeting a single-disease mediator with a traditional monoclonal antibody (mAb) can result in limited efficacy or partial response. Preclinical studies in disease models demonstrated that targeting two or more disease mechanisms is far more effective than targeting a single mechanism, potentially due to the additive or synergistic effect of the dual-targeting strategy. Combining large molecules in the past has been a significant challenge because multi-specificity-based mAbs had poor pharmacokinetics, stability, and manufacturing feasibility. The dual-variable domain immunoglobulin (DVD-Ig) platform, discovered by Abbott scientists, is the first technology to successfully combine the function and specificity of two or more mAbs into one molecule, thereby creating a combination therapy in a single drug. The DVD-Ig approach has distinct technological and scientific advantages compared to mAbs. The technology enables the development of new generation biologics that target multiple disease mediators simultaneously, while displaying excellent drug-like properties and manufacturing efficiency. The approach allows for the creation of new, improved biologic medicines for complex diseases such as cancer and autoimmune diseases.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here